Financial Performance Overview
Sakar Healthcare Limited reported exceptional FY26 results with revenue from operations surging 42% to ₹251.74 crore from ₹177.58 crore in FY25. Net profit demonstrated even stronger growth, increasing 74.8% to ₹30.38 crore. The revenue mix comprised 60.1% export sales (₹151.37 crore) and 39.9% domestic sales (₹100.37 crore), supported by export incentives of ₹0.96 crore and exchange rate gains of ₹1.06 crore.
Operational and Business Highlights
The company's oncology business achieved significant progress with over 60 product contracts and 250 dossiers shared globally, resulting in 12 Marketing Authorisations received during the year. Operational efficiency improved with EBITDA growing 39% to ₹68.89 crore. The balance sheet remained healthy with net worth of ₹324.45 crore and conservative debt-equity ratio of 0.20x, though trade receivables increased to ₹500.83 crore and inventories stood at ₹700.41 crore.
Capital Structure and Financing
Sakar Healthcare secured a ₹31.46 crore term loan from State Bank of India, secured by hypothecation of assets and collateral of industrial land. The company issued 300,000 new equity shares, increasing subscribed capital from ₹219.50 lakh to ₹222.50 lakh, which slightly diluted promoter holding from 53.58% to 52.86%. Capital work-in-progress of ₹3.97 crore reflects ongoing investment in new building construction to support future expansion.
Corporate Governance and AGM Details
The company submitted its Annual Report 2025-26 and Notice of 22nd AGM to NSE pursuant to SEBI LODR Regulations. The 22nd Annual General Meeting is scheduled for September 22, 2026 through Video Conferencing/OAVM. Key agenda items include adoption of financial statements, reappointment of Ms. Visalakshi Chandramouli as director, ratification of Cost Auditors (M/s Dalwadi & Associates), and appointment of Secretarial Auditors (M/s. Kashyap R. Mehta & Partners) for five years.
Compliance and Voting Process
The company confirmed full compliance with Companies Act 2013, SEBI LODR Regulations, and ICSI Secretarial Standards. Remote e-voting through CDSL is available from September 19-21, 2026, with cut-off date of September 15, 2026. The scrutinizer appointment ensures proper oversight of the voting process.
Key Financial Ratios and Metrics
- Current Ratio: 1.28 (down from 1.40)
- Return on Equity: 9.40% (up from 6.13%)
- Net Profit Margin: 12.11% (up from 9.86%)
- Inventory Turnover: 2.17 (down from 2.31)
- Trade Receivables Turnover: 6.23 (down from 6.88)
The combined disclosure presents a comprehensive picture of strong financial performance, strategic business development in oncology, prudent capital management, and robust corporate governance practices.